ABB Powers Tourists to the Niagara Falls with First US Built All-Electric Vessels
3.5.2019 18:45:00 EEST | Business Wire | Press release
Niagara Falls tour operator Maid of the Mist orders two new passenger vessels sailing on pure electric power, enabled by ABB’s technology
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190503005349/en/
Maid of the Mist new passenger vessels sailing on pure electric power, enabled by ABB's technology (Photo: Business Wire)
Visitors to the iconic Niagara Falls will soon be able to experience one of the US’s top landmarks emission-free. Two new Maid of the Mist passenger vessels will be powered entirely by high-capacity battery packs, becoming the first all-electric vessels ever built in the US.
The new vessels will benefit from ABB’s zero-emission technology when they start operating later this year, allowing guests to experience Niagara Falls undisturbed by engine noise, vibration or exhaust fumes from a conventional diesel engine.
Maid of the Mist, one of North America’s oldest tourist attractions, operates from April through to the first week of November, with boats departing for the base of Niagara Falls every 30 minutes, with an estimated 1.6 million guests on board annually.
“We are thrilled to be the US’s first vessel owner to add all-electric ferries to our fleet,” said Christopher M. Glynn, president of Maid of the Mist Corp. “We have chosen ABB to support us in our journey towards more sustainable operation based on their unparalleled experience in marine system integration, as well as efficient and innovative technologies for sustainable transportation.”
“Maid of the Mist’s decisive move towards e-mobility signals a new era in the future of transportation and complements ABB’s commitment to power the world without consuming the earth,” said Peter Terwiesch, President of the Industrial Automation business at ABB, which offers solutions for a wide range of industries, including marine. “Reducing emissions at Niagara Falls is not only important for the natural landmark, but also proves that the technologies enabling sustainable mobility are already available today.”
Each of the vessels will be powered by a pair of battery packs with a total capacity of 316 kWh, split evenly between two catamaran hulls. Having two fully independent power systems on board will increase the resilience of operations by creating a redundancy.
The vessels will charge between every trip while passengers disembark and board. Shoreside charging will only take seven minutes, allowing the batteries to power the electric propulsion motors capable of a total 400 kW (563 HP) output. The power setup will be controlled by ABB’s integrated Power and Energy Management System (PEMS), which will optimize the energy use on board.
The batteries will be charged using hydropower – the largest single renewable energy source for electricity generation in the US, which accounts for 7 percent of the country’s total utility-scale electricity generation. The use of locally produced renewable power will make the energy cycle for the operation of the new Maid of the Mist vessels entirely emission-free.
Sustainable transportation has a crucial role in the fight against climate change, with shipping accounting for 2 to 3 percent of the world’s total greenhouse gas emissions. The International Maritime Organization, a United Nations agency responsible for regulating shipping, has set a global target to cut annual emissions by at least 50 percent by 2050 from 2008 levels.
In addition to integrating the ship-to-shore battery charging connection, ABB will supply the Maid of the Mist newbuilding project with switchboards, drives and the integrated control system, as well as the ABB Ability™ Marine Remote Diagnostic System for remote equipment monitoring and predictive maintenance. ABB Ability™ is ABB’s leading offering of digital solutions and services.
To watch the video, click here.
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190503005349/en/
Contact information
ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland
Media
Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom